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Common Activation of Canonical Wnt Signaling in
Pancreatic Adenocarcinoma
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1Diabetes Center, Department of Medicine, University of California at San Francisco, San Francisco, California, United States of America, 2Cancer
Research Program, Garvan Institute of Medical Research, St. Vincent’s Hospital Campus, Darlinghurst, New South Wales, Australia, 3Department of
Surgery, Bankstown Hospital, Sydney, Australia, 4Gastroenterology Division, Department of Genetics, University of Pennsylvania, Philadelphia,
Pennsylvania, United States of America, 5Comprehensive Cancer Center, Department of Dermatology, University of Michigan, Ann Arbor, Michigan,
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Pancreatic ductal adenocarcinoma (PDA) is an extremely aggressive malignancy, which carries a dismal prognosis. Activating
mutations of the Kras gene are common to the vast majority of human PDA. In addition, recent studies have demonstrated
that embryonic signaling pathway such as Hedgehog and Notch are inappropriately upregulated in this disease. The role of
another embryonic signaling pathway, namely the canonical Wnt cascade, is still controversial. Here, we use gene array
analysis as a platform to demonstrate general activation of the canonical arm of the Wnt pathway in human PDA. Furthermore,
we provide evidence for Wnt activation in mouse models of pancreatic cancer. Our results also indicate that Wnt signaling
might be activated downstream of Hedgehog signaling, which is an early event in PDA evolution. Wnt inhibition blocked
proliferation and induced apoptosis of cultured adenocarcinoma cells, thereby providing evidence to support the
development of novel therapeutical strategies for Wnt inhibition in pancreatic adenocarcinoma.
Citation: Pasca di Magliano M, Biankin AV, Heiser PW, Cano DA, Gutierrez PJA, et al (2007) Common Activation of Canonical Wnt Signaling in
Pancreatic Adenocarcinoma. PLoS ONE 2(11): e1155. doi:10.1371/journal.pone.0001155
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading
cause of cancer death in Western societies. The disease usually
presents at an advanced stage, and as a result only 10 to 20% of
patients are suitable for surgical resection [1]. Presently, non-
operative therapies are widely ineffective, contributing to an
overall 5 year survival-rate of less than 5%. There is now
compelling histopathological and molecular evidence to support
the evolution of PDA through a series of non-invasive duct lesions
called pancreatic intraepithelial neoplasia (PanIN) [2]. Progression
of PanIN lesion is associated with molecular aberrations that
increase in frequency and correlate with advancing cellular atypia
from early stages to invasive cancer [3,4]. Recent studies have
identified deregulation of pathways important in vertebrate
pancreas development, including Notch [5] and Hedgehog [6,7],
in the development and progression of PDA.
Interactions between embryonic signaling pathways ensure
proper organ formation during development. Increasing evidence
suggests that these pathways remain active in a subset of cells
within adult organs and that deregulation of their activity
contributes to the development and progression of certain tumors
[8]. Hedgehog and Wnt signaling are involved in the development
of the pancreas [9–13]. Both pathways appear to be regulated in
a very tight manner during embryogenesis. Inappropriate
activation of Hedgehog signaling during pancreas formation
results in agenesis of this organ [14,15]. A similar result is
observed when Wnt signaling is activated at high levels during
early pancreatic development [10,16]. In contrast, activation of
Wnt signaling predominately in acinar cells results in a significant
increase in pancreas mass [10]. Ectopic activation of Wnt signaling
at early stages of pancreas organogenesis increases Hedgehog
activity [10]. While Hedgehog signaling is known to regulate Wnt
activity in other organs [17], such regulation in developing
pancreatic tissue has not yet been reported.
A large body of evidence supports the notion that uncontrolled
activation of the canonical Wnt pathway induces tumor formation
in the distal gastrointestinal tract [18]. Canonical Wnt signaling is
activated when soluble Wnt ligands form a complex with one of
several FRIZZLED receptors and LRP5/LRP6 co-receptors. This
interaction triggers a cascade of events that results in the inhibition
of ß-CATENIN phosphorylation. Non-phosphorylated ß-CATE-
NIN translocates from the cytoplasm to the nucleus where it binds
to the TCF-LEF family of transcription factors to activate the
transcription of Wnt target genes. Upregulation of Wnt signaling,
mediated by specific mutations in the APC or ß-CATENIN genes,
is thought to play a critical role in the development of several
gastrointestinal tumors [18,19].
Sustained tumor growth due to deregulation of Wnt signaling
independent of mutations that increase pathway activity has been
demonstrated in studies on breast and ovarian cancer [20].
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Similarly, mutations in either APC or ß-CATENIN that are
commonly found in other gastrointestinal cancer are rare in PDA
[21]. However, aberrant cytoplasmic and nuclear expression of ß-
CATENIN, both indicative of canonical Wnt signaling activity
[11,22], are present in a substantial group of PDA and PanIN
samples [23,24]. Moreover, heparan sulfate proteoglycans, known
to regulate Wnt activity, are expressed in pancreatic adenocarci-
noma and positively regulate cancer growth [25]. These data
suggest that Wnt signaling may play a role in PDA despite the
absence of signature mutations in APC or ß-CATENIN.
Nevertheless, activation of the Wnt signaling pathway in
pancreatic cancer has remained controversial [24] and functional
studies addressing a potential contribution of Wnt signaling to
PDA development and progression are currently missing.
Here we identify aberrant expression of Wnt signaling
components in a large cohort of patients with PDA. Whilst only
13% of PDA demonstrate nuclear localization of ß-CATENIN,
65% demonstrate either loss of membranous expression and/or
increased cytoplasmic expression. Similar results were obtained
from the analysis of mouse models of pancreatic cancer.
Assessment of PDA cell lines revealed activation of Wnt signaling
and pathway inhibition showed that cancer cell survival and
proliferation depends in part on Wnt activity. Increased levels of
Hedgehog signaling constitute one of the earliest changes in PanIN
lesions. Our results show that Hedgehog signaling activates ß–
CATENIN/Wnt signaling in transgenic mice and untransformed
pancreatic duct cells, suggesting that Hedgehog may play a role in
upregulating Wnt activity in PDA.
RESULTS AND DISCUSSION
A number of recent reports have characterized the role of Wnt
signaling during pancreas development and function of the adult
organ [10–13,26,27]. In contrast, the exact role canonical Wnt
signaling plays in the formation and progression of PDA remains
unclear. While robust activation of the pathway due to signature
mutations in components of the Wnt cascade commonly observed
in other gastrointestinal cancers have not been found in PDA,
immunohistochemical analysis against ß-CATENIN, the key
mediator of this pathway, suggests a contribution of Wnt signaling
during PanIN progression and in PDA [23,24,28]. In normal adult
pancreatic tissue b2CATENIN is exclusively localized to the cell
membrane and both cytoplasmic and nuclear localization of ß-
CATENIN is commonly regarded as an indicator of active
canonical Wnt signaling [11,22]. Our analysis of 136 human PDA
samples revealed nuclear b-CATENIN expression in 17 (13%) and
cytoplasmic expression in 89 (65%) samples (Figure S1). Thus,
abnormal localization of b2CATENIN, either nuclear or
cytoplasmic, was detected in the majority of the tumor samples.
To obtain more quantitative information about the level of Wnt
signaling, we performed expression profiling of Wnt pathway
components in PDA with genechip microarray. This analysis
demonstrated aberrant expression of numerous components of the
Wnt pathway in 12 PDA samples when compared to control tissue
(6 normal specimens from the cancer patients and 12 samples of
healthy pancreas) (Table S1). Expression of members of the
FRIZZLED receptor family (FRIZZLED 2, 7 and 9), their ligands
(WNT 2, 3, 4, 5A, 5B, 6, 8B and 11), and putative inhibitors of
Wnt signalling (SECRETED FRIZZLED-RELATED PROTEIN
3 and 4 and DICKKOPF genes 1, 2 and 3) was increased in PDA
compared to normal pancreas. Central pathway inhibitors such as
ICAT were downregulated. In addition, expression of transcrip-
tional target genes of ß-CATENIN, including CYCLIN D1,
FIBRONECTIN, RETINOIC ACID RECEPTOR c, CYCLO-
OXYGENASE 2, uPAR and MMP-7, were upregulated. Thus,
the overall pattern, particularly the upregulation of direct
transcriptional targets of Wnt signaling, suggests increased
pathway activity. However, it should be noted that the overall
increases in Wnt signaling targets appear smaller than those
observed in other tumors, including colon cancer. This might be
due to the fact that high level Wnt signaling requires mutations in
pathway components, including ß-CATENIN and APC, that are
not commonly observed in PDA. This raised the question of
whether Wnt signaling is controlled by other signaling pathways
known to be deregulated in PanIN and PDA.
Increased Wnt signaling in a mouse model of PDA
Deregulation of Kras activity is observed in the vast majority of
human PDA [1]. Activating mutations in the Kras oncogene have
been observed in PanIN lesions, suggesting that deregulation of
Ras signaling is a key component during the transformation of
epithelial cells [29,30]. Support for this notion comes from studies
in Pdx-Cre;KrasG12D transgenic mice in which expression of the
prevalent KrasG12D mutation in pancreatic epithelial cells results in
the formation of tumors that resemble human PDA [31]. To
determine whether increased Wnt signaling is a common
phenomenon during PDA formation in different species, we
examined pancreata from Pdx-Cre;KrasG12D and Pdx-Cre;K-
rasG12D;p53f/+ mice by immunohistochemistry. In support of the
human data, PanIN lesions in Pdx-Cre;KrasG12D and Pdx-Cre;K-
rasG12D;p53f/+ mice displayed changes in ß-catenin localization and
increased expression of Tcf4, a mediator of canonical Wnt
signaling (Fig. 1A–D and Table S1). Quantitative PCR for Wnt
target genes showed a moderate increase in axin2 expression in
Pdx-Cre;KrasG12D pancreata marked by PanIN lesions (Fig. S2). In
order to determine whether accumulation of b-catenin effectively
correlated with Wnt signaling activity we generated Pdx-Cre;K-
rasG12D;TOPGal mice. Due to the expression of the LacZ-reporter
gene under control of Wnt signaling responsive TCF-binding sites,
the TOPGal mice provide an excellent means to identify cells
within a given tissue that respond to canonical Wnt signaling [32].
While ß-galactosidase staining is absent in pancreata of control
mice (wild type, TOPGal and Pdx-Cre;TOPGal animals were used as
negative controls) (Fig. 1E and data not shown), pronounced ß-
galactosidase activity is noted in epithelial cells of PanIN lesions of
compound Pdx-Cre;KrasG12D;TOPGal mice (Fig. 1F). Thus, immu-
nohistochemical staining, quantitative PCR for canonical Wnt
target genes, and analysis of Wnt reporter mice indicate increased
Wnt/ß-catenin signaling during the formation of PDA in human
samples and mouse models of this disease.
The canonical Wnt signaling arm is active in human
pancreatic adenocarcinoma
To understand whether sustained Wnt signaling is important for
cancer cell proliferation we included established pancreatic cancer
cell lines in our analysis. First, we used RT-PCR to demonstrate
expression of Wnt ligands (WNT 11, WNT 7b, WNT 5b, WNT 2b),
Wnt ligand co–receptors LRP5 and LRP6, and transcription
factors TCF3 and TCF4, in 26 human PDA cell lines derived from
either primary or metastatic PDA (Fig. 2A). Expression of TCF1
and LEF1, transcriptional activators of the canonical Wnt
signaling arm in other tissues, were expressed only in a subset of
cell lines. These data suggest that the proteins necessary for active
Wnt signaling are expressed at significant levels in all PDA cell
lines analyzed.
To quantitatively evaluate the degree of Wnt signaling activity
in a subset of these cell lines (n = 9) we measured luciferase
expression controlled by concatemers of ‘TCF optimal sites’ (Top)
Wnt in Pancreatic Cancer
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upstream of a minimal thymidine kinase (TK) promoter element
[33]. Concatemers of TCF ‘far from optimal sites’ (Fop) upstream
of the TK-promoter served as control for Wnt independent, basal
activity of the reporter construct. We detected activation of the
Top-Flash reporter in each of the nine different adenocarcinoma
cell lines tested (Fig. 2B). The majority of cell lines displayed a 3 to
5 fold relative activation of the Top-FLASH reporter. In
comparison, relative Top-FLASH activity in the SW480 and
HCT116 colon cancer cell lines was greater than that seen in any
PDA cell lines (.6 Top/Fop ratio and .10 Top/Fop ratio
respectively, data not shown), indicating that the majority of PDA
cell lines show a moderate, but significant increase in Wnt activity.
Inhibition of Wnt signaling reduces cell proliferation
and increases apoptosis in pancreatic
adenocarcinoma cells
Four pancreatic adenocarcinoma cell lines were selected for in
depth analysis of the requirement of Wnt signaling in PDA cells.
Two well-established lines (CFPAC, BxPC3), a line with high
metastatic potential (L3.6sl), and a line closely resembling
a primary tumor phenotype (Panc4.21) were examined [34]. All
four lines express significant levels of non-phosphorylated ß-
CATENIN, another reliable marker of active Wnt/ß-CATENIN
signaling (data not shown). The requirement of Wnt/ß-CATENIN
signaling for PDA cell proliferation and survival was assessed by
ectopically expressing known pathway inhibitors. Co-transfection
with the endogenous Wnt inhibitor, Icat [35] or a dominant negative
form of Lef-1 (dn-Lef-1), resulted in reduction of Top-Flash activity in
the 4 PDA cell lines tested (Fig. 3A). In contrast, FOP-Flash activity
was not affected by Icat or dn-Lef co-transfection (data not shown).
Previous studies have shown effective reduction of Wnt/ß-
CATENIN signaling in colon cancer cell lines upon treatment with
siRNAs directed against ß–CATENIN [36]. Using a similar strategy,
we observed a significant and dose dependant reduction in ß-
CATENIN protein levels in pancreatic cancer cell lines transfected
with anti-ß-CATENIN siRNA (Fig. 3B). Thus, Wnt/ß-CATENIN
signaling in PDA cells can be blocked by treatment with three
distinct and well-established pathway inhibitors.
Wnt/ß-CATENIN signaling controls cell proliferation and
survival in tissues other than pancreas. To test whether inhibition
of Wnt signaling is sufficient to block cell proliferation in
pancreatic adenocarcinoma cells, we measured BrdU incorpora-
tion in cells transiently transfected with Wnt inhibitors Icat and dn-
Lef-1. The presence of an IRES sequence driving the expression of
eGFP in the Icat- and dn-Lef-1-constructs allowed sorting and
comparison of GFP/target gene negative control and GFP/target
gene positive cells by flow cytometry. Transfection of the four
pancreatic cancer cell lines with either Icat or dn-Lef-1 led to
a significant decrease in cell proliferation and a marked increase in
apoptosis (Fig. 3C, E). Similar results were obtained when ß-
CATENIN function was specifically blocked with anti-ß-CATENIN
siRNA [36] (Fig. 3D, F and Figure S3). Notably, we found that the
reduction in cell proliferation and the increase in apoptosis upon ß-
CATENIN knockdown was dose-dependent. The significant in-
hibition of cell proliferation and induction of apoptosis via inhibition
of Wnt signaling through three different mechanisms strongly
supports a role for Wnt signaling in PDA growth and survival.
Previous reports have demonstrated an important role for ß-
CATENIN in cell adhesion as part of a protein complex that
includes E-cadherin. Therefore, disruption of this protein
aggregate through ectopic expression of Icat or treatment with
anti-ß-CATENIN siRNAs could affect cell viability by perturbing
critical functions of E-cadherin rather than via decreased Wnt
signaling. The E-CADHERIN expression pattern in the cell lines
was unaffected by ß-CATENIN- siRNA knockdown (data not
shown). In addition, a similar reduction in cell proliferation and
increase in apoptosis was seen with dn-Lef-1 transfection, that
specifically blocks ß-CATENIN mediated transcription (Fig. 3C,
E). These results suggest that inhibition of Wnt/ß-CATENIN
transcriptional activity, rather than alteration in ß-CATENIN/E-
Figure 1. Active Wnt signaling in a mouse model of PDA. A.
Immunostaning for b-Catenin in a control pancreas is confined to the
plasma membrane. B. In contrast, cytoplasmic b-catenin expression is
observed in PanIN lesions and tumor of a 8-week old Pdx-
Cre;KrasG12D;p53f/+ pancreas. The tumor is outlined in red. Note the
accumulation of b-catenin in the epithelial cells (brown staining). Two
PanIN lesions are outlined in light blue. The black arrow points at cells
that have retained membranous b-catenin, while the red arrows point
at areas of accumulation of b-catenin in the cytoplasm. C. Tcf4 is
expressed at a low level in ductal cells in a wild-type mouse pancreas. D.
Elevated expression of Tcf4 in PanIN lesions of a 12-week old Pdx-
Cre;KrasG12D pancreas. E, F. LacZ staining of pancreatic tissue of adult
(6 months old) Top-gal (E) and Pdx-Cre;KrasG12D;Top-gal (F) mice. No
staining is present in the Top-gal pancreas. ß-galactosidase activity is
detected in the PanIN lesions of the Pdx-Cre;KrasG12D;Top-gal pancreas,
indicating activation of the canonical Wnt pathway. The black bar
represents 35 mm in A-D, 67.5 mm in E, F.
doi:10.1371/journal.pone.0001155.g001
Wnt in Pancreatic Cancer
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CADHERIN interaction, is critical for the observed effects on cell
proliferation and apoptosis.
Hedgehog signaling regulates Wnt signaling in
untransformed pancreatic ductal epithelial cells and
in pancreatic cancer cells
Canonical Wnt/ß–catenin signaling is absent from normal mature
pancreata [11] (Figure 1A, E). Our data and previously published
reports show induction of ß-catenin signaling during PanIN
formation, raising the question of the mechanism by which Wnt/
ß-catenin signaling is induced. Hedgehog signaling, another
embryonic signaling pathway, has previously been implicated in
the initiation and growth of pancreatic adenocarcinoma [6,7] as
well as regulation of Wnt activity during mammalian organ
development [37,38]. Pancreatic ductal epithelial cells may
constitute the putative cell of origin for PDA [39]. A previously
described protocol allows the isolation of pancreatic duct cells
(PDCs) from mature murine pancreas [40]. We used these cells to
investigate the effect of Hedgehog signaling on Wnt activity in
non-transformed epithelial cells. Ectopic activation of Hedgehog
activity in PDCs was obtained either through expression of
a dominant-active version of GLI2 [41] or a dominant-active form
of Smoothened (SmoA1). Expression of the transgenes was confirmed
by immunofluorescence (Fig. 4C and data not shown). As
expected, the activity of the Hedgehog pathway was significantly
up-regulated in PDC-SmoA1 and PDC-GLI2 compared to PDCs,
as measured by luciferase activity of a Hedgehog reporter
construct, Gli-BS (Fig 4A and data not shown). Interestingly, the
activity of the Wnt reporter TOP-Flash was also significantly
increased (Fig 4A), thus showing that activation of Hedgehog
signaling upregulates Wnt activity in pancreatic duct cells. These
Figure 2. Wnt signaling is active in human pancreatic adenocarcinoma cell lines. A. RT-PCR analysis for components of the Wnt signaling pathway
in 26 human pancreatic adenocarcinoma cell lines: 1-MiaPaca2; 2-Panc1; 3-CFPAC1; 4-HPAFII; 5-Capan-2; 6-AsPC1; 7-Hs766T; 8-BxPC3; 9-COLO357; 10-
L3.3; 11-L3.6sl; 12-L3.6pl; 13-SW1990; 14-SU86.86; 15-PL45; 16-HPAC; 17-MPanc96; 18-Panc1.28; 19-Panc2.03; 20-Panc2.13; 21-Panc3.27; 22-Panc4.21;
23-Panc5.04; 24-Panc6.03; 25-Panc8.13; 26-Panc10.05. B.Wnt signaling is active in all nine pancreatic adenocarcinoma cell lines tested, as indicated by
the activation of the Top-Flash reporter (black) compared to the basal activity of the Fop-Flash reporter (white). Renilla luciferase was used to
normalize for transfection efficiency. Error bars are shown as St. Dev. P-values were calculated in comparison to control Fop-Flash activity (white bars).
*, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0001155.g002
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Figure 3. Inhibition of Wnt signaling blocks adenocarcinoma cell proliferation. A. Inhibition of Wnt signaling in four pancreatic adenocarcinoma
cell lines. Cells transfected with Fop-Flash (white) or Top-Flash (light gray) reporter constructs were co-transfected with an empty expression vector or
an expression vector containing the Wnt-inhibitors Icat (dark gray) or dominant-negative Lef1 (dnLef; black). Fop-Flash activity was not affected by
either Icat or dn-Lef co-transfection, thus only one Fop-Flash data point is shown. The significant reduction of Top-Flash activity in cells expressing the
inhibitors indicates inhibition of Wnt signaling in pancreatic cancer cells. P-values were calculated in comparison to Top-Flash activity (light gray bar).
B. Immunofluorescent staining against b-CATENIN in four pancreatic adenocarcinoma cell lines after transfection with a siRNA directed against b-
CATENIN. The b-CATENIN protein levels are dramatically decreased in a dose-dependent manner following b-CATENIN siRNA transfection. Control
siRNA transfected cells have b-CATENIN levels indistinguishable from those found in untransfected cells (untreated). C. Transfection with an Icat–IRES-
eGFP expression vector (Icat, black) or dominant negative Lef – IRES-eGFP (dnLef, gray) strongly inhibits growth of four pancreatic cancer cells lines,
measured as the ability to incorporate BrdU. Control cells (white) were transfected with the IRES-eGFP expression vector; all cells were harvested
48 hrs after transfection. P-values are shown in comparison to control transfected cells. D. Proliferation is reduced in a dose-dependent manner in
cells treated for 48hrs with anti-ß-CATENIN siRNA (dark grey, black,) compared to control cells (white). Untreated (no siRNA), white columns; control
siRNA (300 nM), light grey columns; anti-ß-CATENIN siRNA (100 nM), dark grey columns; anti-ß-CATENIN siRNA (300 nM), black columns. P-values are
shown in comparison to untreated controls (white columns). E. Level of apoptosis, measured as cells with DNA content lower than the diploid
amount, in control transfected cells (white) or cells transfected with Icat (black) or dominant negative Lef (grey). F. Treatment with anti-ß-CATENIN
siRNA increases levels of apoptosis in a concentration-dependent manner. Error bars are shown as St. Dev.; P-values, #, not significant; *, p,0.05;
**, p,0.01.
doi:10.1371/journal.pone.0001155.g003
Wnt in Pancreatic Cancer
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Figure 4. Hedgehog signaling regulates Wnt activity in untransformed duct cells. A. Activity of the Wnt and Hedgehog pathways in control PDCs
and stable clones transfected with dominant-active forms of GLI2 (PDC-GLI2). Activation of the Hedgehog pathway in two PDC-GLI2 clones (#1, #2)
results in significant increase in Wnt signaling activity. B. Activity of the Wnt and Hedgehog pathways in control PDCs and PDCs stably transfected
with a dominant active form of Lef1 (PDC-Lef–da). Activation of the Wnt pathway in the PDC-Lef–da cells does not affect the level of Hedgehog
signaling. Error bars are shown as St. Dev. P-values,#, not significant; **p,0.01. C. PDC cells were stably transfected with a myc-tagged version of the
constitutive active form of GLI2 (GLI2-myc fusion protein). Immunostaining using an anti-myc antibody confirms GLI2 expression in transfected cells.
Untransfected PDC cells are shown as negative control. Immunostaining for Tcf4 is not detectable in wt PDC cells, but it is strongly upregulated in
PDC-GLI2 cells. D. Immunohistochemistry analysis of Panc4.21 and L3.6sl pancreatic cancer cell lines shows that inhibition of the Wnt signaling
pathway using anti-b-CATENIN siRNA (100nM) results in a strong downregulation of TCF4 expression compared to control cells (transfected with an
unrelated siRNA). Similarly, inhibition of the Hedgehog pathway using an anti-GLI1/2 siRNA (100 nM) results in TCF4 downregulation; the same effect
is observed in cells treated with a combination of anti-b-CATENIN and anti-GLI1/2 siRNA (each 100nM). E. Quantification of Tcf4 expression in PDC
(white) and PDC-GLI2 (black) cells. At least 100 cell nuclei were scored for Tcf4 expression and the percentage of positive nuclei is shown in the
histogram. F. Quantification of TCF4 positive nuclei following siRNA treatment in human PDA cell lines. At least 100 nuclei were scored for each
category: control siRNA (white), anti-b-CATENIN siRNA (light gray), anti-GLI siRNA (dark gray) and a combination of both siRNAs (black). Error bars are
shown as St. Dev.; p-values #, not significant; *p,0.05; **, p,0.01. G. In wild-type mouse pancreas tissue, b-catenin is only localized at the cell
membrane. H. Presence of nuclear b-catenin in a fraction of the tumors cells in an undifferentiated pancreatic tumor of a Pdx-Cre;CLEG2 mouse. I.
Cytoplasmic and nuclear b-catenin staining in the PanIN lesions of a Pdx-Cre;CLEG2;KrasG12D pancreas. The black bar represents 35 mm in G-I.
doi:10.1371/journal.pone.0001155.g004
Wnt in Pancreatic Cancer
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findings support the notion that the induction of Wnt activity in
human PDA can occur in the absence of signature mutation in
APC or ß-CATENIN that are commonly found in other cancers.
To test whether Wnt signaling regulates Hedgehog activity,
PDCs were transfected with an expression vector coding for
a dominant-active form of Lef1, (Lef1-da) followed by an IRES-
eGFP sequence. Target gene expression in pools of transfected cells
was verified by Western blot and by flow cytometry using eGFP as
a marker (data not shown). Top–Flash reporter assays confirmed
an approximately 4–fold increase in Wnt activity in PDC–Lef1–da
cells compared to PDCs. However, ectopic activation of Wnt
signaling did not induce luciferase activity of the Hedgehog
responsive Gli-BS reporter (Fig. 4B).
Hedgehog signaling regulates expression of TCF4 in
pancreatic duct and cancer cells
While a number of studies have demonstrated that Hedgehog and
Wnt pathways regulate each other’s activity, the molecular
mechanisms underlying this regulation remain unresolved. Activa-
tion of the canonical Wnt pathway requires the physical interaction
of nuclear ß-CATENIN and TCF/LEF transcription factors.
b2CATENIN and factors of the TCF/LEF family of DNA-binding
molecules are the downstream effectors of theWnt signaling cascade.
TCF4 is expressed in the gastrointestinal tract and in tumors of
gastrointestinal origin. Formation of the b2CATENIN/TCF4
complex is regulated at different levels, such as accumulation and
localization of b2CATENIN [42], interaction between the two
factors, and ability of TCF4 to bind DNA [43]. TCF4 mRNA is
expressed at high levels in all pancreatic adenocarcinoma cell lines
analyzed (Fig. 2A). Little Tcf4 protein was detected in a small
proportion of pancreatic duct cells, however, GLI2-mediated
activation of Hedgehog signaling induced robust Tcf4 expression
in pancreatic duct cells (Fig. 4C, E). To test whether Hedgehog
signaling controls TCF4 expression in pancreatic cancer cells, we
treated Panc4.21 and L3.6sl cells with siRNAs directed against ß-
CATENIN as well as GLI1/GLI2. Interestingly, inhibition of either
Hedgehog or Wnt signaling resulted in loss of nuclear TCF4
expression (Fig. 4D, F). In addition, treatment of the pancreatic
cancer cells with the Hedgehog inhibitor cyclopamine resulted in
a significant down-regulation of TCF4 protein and Top-Flash
activity in the CFPAC, Panc4.21 and L3.6 cell lines (Fig. S4). The
observation that TCF4 levels and Top-Flash activity were not
affected in the cyclopamine insensitive cell line BxPC3 cells further
support the notion that TCF4 expression is regulated in response to
Hedgehog signaling. Thus, Hedgehog signaling regulates the Wnt
pathway at least in part by affecting the concentration of nuclear
TCF4 in pancreatic cancer cells.
To test whether Hedgehog activation is sufficient to induce
Wnt/ß-catenin signaling in vivo, we analyzed transgenic mice
marked by ectopic expression of an activated version of GLI2 in
pancreatic epithelium (Pdx-Cre;CLEG2). We have previously
reported that forced activation of Hedgehog signaling in Pdx-
Cre;CLEG2 mice results in the formation of undifferentiated tumors
[44]. Immunohistochemical analysis revealed that tumor cells are
marked by cytoplasmic and nuclear ß-catenin expression (Fig. 4H).
Thus, epithelial-specific activation of Hedgehog signaling is
sufficient to induce Wnt/ß-catenin signaling in pancreatic cells.
Furthermore, nuclear ß-catenin is observed in PanIN as well as
undifferentiated tumors that form in mice in which both Kras and
Hedgehog signaling are deregulated (Pdx-Cre;CLEG2;KrasG12D,
Fig. 4I). Summarily, our data from human, transgenic mouse
and cell culture experiments suggest that Wnt/ß-catenin signaling
is commonly activated in preneoplastic lesions and PDA and that
the activation of the pathway is regulated at least in part by
increased Hh signaling.
Notably, both Hedgehog and Wnt signaling appear to be
important for the survival of pancreatic adenocarcinoma cells. This
raises the question whether the cooperation between these pathways
is restricted to the pancreas or whether similar mechanisms can also
be found in other tumors. With the exception of the colon where
conflicting results regarding the relationship between Hedgehog and
Wnt signaling have been reported [45,46], activation rather than
inhibition of both pathways is typically correlated with tumor
formation [47]. Hedgehog and Wnt activity have been noted in
a number of different tumors and future studies will analyze whether
combined antagonist treatments could present novel therapeutic
options for these tumors. This is of particular importance as novel,
more efficient and more specific inhibitors of both pathways are
currently being developed [48,49].
MATERIALS AND METHODS
Mouse strains
Pdx1-Creearly mice ([10,50]) were intercrossed with CLEG2 mice (A.
Ermilov et al., in preparation ;[44]) and with LSL-KrasG12D
mice (a gift from David Tuveson referred to as KrasG12D
throughout the text) ([31]) to generate either double or triple
mutants: Pdx-Creearly;KrasG12D , Pdx-Creearly;CLEG2 and Pdx-Creearly;
CLEG2;KrasG12D. Pdx-Creearly;KrasG12D mice were crossed with the
Top-gal Wnt reporter mice ([32]). All studies were conducted in
compliance with University of California IACUC guidelines.
Immunohistochemistry and Immunofluorescence
Histological analysis of tissues was performed as described
previously [44]. The following primary antibodies were used:
mouse anti-ß-catenin (1:200 dilution, Becton and Dickinson, NJ),
mouse anti-Tcf4 (clone 6H5-3, 1:100 dilution, Upstate, NY). For
immunohistochemistry, we used a biotinylated anti-mouse anti-
body (Jackson immunoresearch, PA) at a 1:300 dilution. 3–39-
Diaminobenzidine tetrahydrochloride was used as a chromogen.
Bright-field images were acquired using a Zeiss Axio Imager D1
scope. Alternatively, we used a FITC anti-mouse secondary
antibody (Jackson immunoresearch, PA), and the slides were
mounted using Vectashlield mounting medium vith DAPI (Vector
laboratories, CA). Immunofluorescent images were acquired using
an Axioscop 2 plus microscope (Zeiss, Germany).
X-gal Staining
Mice were perfused with ice-cold fixative [0.25% glutaraldehyde in
phosphate-buffered saline (PBS)]. Pancreas samples were fixed for
90 minutes at 4uC. Tissues were then washed with PBS containing
2 mM MgCl2 for 1 hour and stained with LacZ solution (1 mg/ml
X-gal, 5 mMpotassium ferricyanide, 5 mMpotassium ferrocyanide,
2 mM MgCl2, 0.02%(v/v) NP40, and 0.01%(w/v) sodium-deox-
ycholate in PBS) at room temperature for 24 hours. After staining,
tissues were post-fixed with buffered formalin, embedded in paraffin,
sectioned, and counterstained with nuclear fast red.
Cell culture and transfection
Tumor cell lines and cell culture protocols were previously
described [7]. PDC cells growth conditions were previously
published ([40] [51]). Cells were transfected using Effectene
reagent (QIAGEN, Germany) according to the manufacturer’s
instructions. For transient transfections, the cells were harvested 24
to 48 hrs after transfection, and the luciferase and renilla acivity
were assayed using the dual luciferase kit (Promega, WI). Stable
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transfectant cells were generated by selecting with G418 at
a concentration of 300 mg/ml. Single clones were isolated and
amplified.
RT-PCR
RNA from pancreatic cancer cells and PDCs was prepared using
TRIzol reagent (Invitrogen, CA). 2 mg of total RNA were treated
with DNAse RQ1 (Promega) prior to cDNA synthesis (using
random hexamers and Superscript II reverse transcriptase,
(Invitrogen, CA). The oligonucleotide sequences are described in
the supplemental information (Methods S1).
Anti-sense RNAs
Anti-b-catenin and anti-GLI1 siRNA sequences were previously
described ([36] [52]). The Gli2 anti-sense siRNA sequence was: 59-
ACACCAACCAGAACAAGCAdTdT-39. The siRNAs were syn-
thesized by Dharmacon, Inc. (CO). The siRNAs were transfected
using oligofectamine reagent (Invitrogen, CA) according to the
manifacturer’s instructions.
BrdU incorporation assay
BrdU incorporation assays were performing using the BD
Biosciences BrdU flow kit according to the manufacturer’s
instructions.
Additional methods are provided in Methods S1.
SUPPORTING INFORMATION
Figure S1 Immunostaining of b-CATENIN in human normal
and cancer tissues. A. In control human pancreas b-CATENIN is
localized at the cell membrane in both acinar and duct cells. B, C,
D. In three different human PDA samples b-CATENIN is
localized predominantly in the cytoplasm (D) and nucleus (B,C).
Found at: doi:10.1371/journal.pone.0001155.s001 (9.42 MB TIF)
Figure S2 Quantitative PCR for Wnt target genes (axin2, Lef1,
Mmp-7, cyclinD1, Dkk2 and Dkk3) in pancreatic samples isolated
from three wild type control and three Pdx-Cre;KrasG12D mice.
All mice analyzed were 6 months old. Data are presented
compared to expression of the household gene GUS.
Found at: doi:10.1371/journal.pone.0001155.s002 (0.36 MB TIF)
Figure S3 Inhibition of Wnt signaling induces apoptosis in
pancreatic cancer cell lines. A. Relative apoptosis is measured by
FACS using an anti-cleaved caspase 3 antibody in cells transfected
with a control siRNA (control, white bars) or b-catenin siRNA
(black bars). B. Immunostaining for cleaved caspase 3 in cells
transfected with a control siRNA or b-catenin siRNA.
Found at: doi:10.1371/journal.pone.0001155.s003 (1.78 MB TIF)
Figure S4 The Hedgehog signaling pathway acts upstream of the
Wnt signaling pathway in pancreatic cancer cells. A. Activity of the
Top-Flash vector in pancreatic adenocarcinoma cells (black bars) is
inhibited in response to cyclopamine (gray bars), an inhibitor of the
Hedgehog signaling pathway. The first P-values indicate statistical
significance in Top-Flash activation (black bars) in comparison to
Fop-Flash activity (white bars). The second P-values show
significance of reduction in Top-Flash activity upon cyclopamine
treatment (gray vs black bars). B. Immunostaining of pancreatic
cancer cells grown in control conditions or treated with cyclopamine
for 24 hrs. With the exception of BxPC# cells, cyclopamine
treatment strongly inhibits TCF4 expression in the cell lines
analyzed. Green: anti-TCF4 antibody; blue: DAPI. C. Quantifica-
tion of the percentage of TCF4 positive nuclei in control cells (white
bars) and in cyclopamine-treated cells (black bars). P-values are
shown in comparison to the control cells. Error bars are shown as St.
Dev.; p-values #, not significant; *p,0.05; **, p,0.01.
Found at: doi:10.1371/journal.pone.0001155.s004 (1.71 MB TIF)
Table S1 Upregulation of Wnt receptors, Wnt ligands and b-
CATENIN itself as well as downregulation of some inhibitors of
Wnt signaling (IDAX and ICAT), together with genes whose
transcription is mediated by b-CATENIN, suggests activation of
Wnt signaling in PDA.
Found at: doi:10.1371/journal.pone.0001155.s005 (0.18 MB
DOC)
Methods S1
Found at: doi:10.1371/journal.pone.0001155.s006 (0.05 MB
DOC)
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